000			02058cam a2200337 a 4500
003			EG-GiCUC
005			20250223032018.0
008			180626s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2017.Mi.P
100	0		_aMichael Magdy Farag Abdelmalak
245	1	2	_aA pharmaceutical study on modified drug delivery systems containing a short acting drug / _cMichael Magdy Farag Abdelmalak ; Supervised Soad A. Yehia , Nevine S. Abdelmalak
246	1	5	_aدراسة صيدلية عن نظم توصيل معدلة تحتوى على عقار قصير المفعول
260			_aCairo : _bMichael Magdy Farag Abdelmalak , _c2017
300			_a185 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aZaleplon is a hypnotic drug indicated for the short term management of insomnia for sleep induction. Also it has shown efficacy in treatment of middle of night insomnia without hangover effects. Zaleplon undergoes an extensive hepatic first pass metabolism leaving only 30% systemically available. Its elimination half-life is I hour. ZLP belongs to BCS class II with poor solubility and high permeability. Despite being rapidly absorbed after oral adminstration, the poor aqueous solubility of ZLP limits its dissolution rate and delays its onset of action. The best achieved formula of chaper I FM5 showed optimum mucoadhesion strength (1507.12±62.238 mcg/cm²) and controlled release profile (Q₃hr= 29.06%±0.73% and Q₁₂hr= 87.24%±1.71%) with desirability {u2243} 0.7
530			_aIssued also as CD
653		4	_abi-layered chronopatches
653		4	_aPulsatile release
653		4	_aZaleplon
700	0		_aNevine Shawky Abdelmalak , _eSupervisor
700	0		_aSoad Ali Yehia , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c66638 _d66638